Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years

Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years Publisher Pubmed

Ghadiri F¹ ; Sahraian MA¹ ; Baghbanian SM² ; Ashtari F³ ; Razazian N⁴ ; Majdinasab N⁵ ; Poursadeghfard M⁶ ; Hatamian H⁷ ; Harirchian MH⁸ ; Beladimoghadam N⁹ ; Azimi A¹ ; Sharifipour E¹⁰ ; Hosseini S¹¹ ; Bayat A¹² Show All Authors

Ghadiri F¹
Sahraian MA¹
Baghbanian SM²
Ashtari F³
Razazian N⁴
Majdinasab N⁵
Poursadeghfard M⁶
Hatamian H⁷
Harirchian MH⁸
Beladimoghadam N⁹
Azimi A¹
Sharifipour E¹⁰
Hosseini S¹¹
Bayat A¹²
Kamali H¹³
Hosseni Nejad Mir N¹⁴
Faraji F¹⁵
Mozhdehipanah H¹⁶
Modara F¹⁷
Navardi S¹
Heidari H¹
Ayoubi S¹
Naser Moghadasi A¹
Eskandarieh S¹

Source: Multiple Sclerosis and Related Disorders Published:2022

Abstract

Background: Iran, as a middle income country, is one of the places with high and rising prevalence of multiple sclerosis (MS). Regarding the substantial economic burden, reviewing the trend in prescribed disease modifying treatments (DMTs) could be of help. Here we studied the DMT information of nearly 14000 MS cases and its trends change for 30 years to improve health services to patients. Methods: The population base of this descriptive-analytical (cross-sectional) study consisted of all MS patients in the nationwide MS registry of Iran (NMSRI), up to August 1, 2021. Registrars from 15 provinces, 24 cities, 13 hospitals,8 MS associations, 16 private offices, and 7 clinics had entered the data. Results: Overall, 14316 cases were enrolled. The majority (76.1%) were female. The youngest and eldest patients were 5 and 78 years old, respectively. Diagnosis delay was under one year in most cases (median: 0, IQR: 0 – 1). Most (61.4%) had RRMS. Generally, platform injectables (IFN beta, glatiramer acetate) were the most used DMTs until 2010. It seems that introduction of newer agents (antiCD20s and oral DMTs) resulted in a decrease in the use of former drugs since around 2015. Some unusual practices are prominent such as using not approved DMTs for PPMS over the years, or administering high efficacy drugs like natalizumab for CIS. The results indicate the remaining popularity of first line injectable DMTs in female and pediatric patients. Discussion: Mean age (SD) at onset in our study (29 ± 8.8) is near the statistics in Asia and Oceania (28 ± 0.7). Concerns about COVID-19 had a noticeable impact on administering high efficacy drugs like rituximab and fingolimod. However, in male patients this approach has not been the case. It may be related to more aggressive disease course in this group. The other possible explanation could be planning for pregnancy in female cases. The popularity of platform injectable drugs in pediatric MS may be related to its favorable safety profile over the years. Another point in this group, is the superiority of rituximab over other highly efficient medications. © 2022

Related Docs

View other Related Docs

1. Late-Onset Multiple Sclerosis in Iran: A Report on Demographic and Disease Characteristics, Multiple Sclerosis and Related Disorders (2023)

2. The Epidemiologic Trend of Multiple Sclerosis in Razavi Khorasan Province, Iran in Fifteen-Year Period, Multiple Sclerosis and Related Disorders (2025)

3. Epidemiological Parameters of Multiple Sclerosis in Chaharmahal and Bakhtiari Province, Iran, Current Journal of Neurology (2023)

Experts (# of related papers)

View all Related Experts

Mohammad Ali Sahraian (14)

Sharareh Eskandarieh (12)

Style	Citing Format
MLA	Ghadiri F, et al.. "Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years." Multiple Sclerosis and Related Disorders, vol. 61, no. , 2022, pp. -.
APA	Ghadiri F, Sahraian MA, Baghbanian SM, Ashtari F, Razazian N, Majdinasab N, Poursadeghfard M, Hatamian H, Harirchian MH, Beladimoghadam N, Azimi A, Sharifipour E, Hosseini S, Bayat A, Kamali H, Hosseni Nejad Mir N, Faraji F, Mozhdehipanah H, Modara F, ... Eskandarieh S (2022). Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years. Multiple Sclerosis and Related Disorders, 61(), -.
Chicago	Ghadiri F, Sahraian MA, Baghbanian SM, Ashtari F, Razazian N, Majdinasab N, Poursadeghfard M, et al.. "Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years." Multiple Sclerosis and Related Disorders 61, no. (2022): -.
Harvard	Ghadiri F et al. (2022) 'Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years', Multiple Sclerosis and Related Disorders, 61(), pp. -.
Vancouver	Ghadiri F, Sahraian MA, Baghbanian SM, Ashtari F, Razazian N, Majdinasab N, et al.. Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years. Multiple Sclerosis and Related Disorders. 2022;61():-.
BibTex	@article{ author = {Ghadiri F and Sahraian MA and Baghbanian SM and Ashtari F and Razazian N and Majdinasab N and Poursadeghfard M and Hatamian H and Harirchian MH and Beladimoghadam N and Azimi A and Sharifipour E and Hosseini S and Bayat A and Kamali H and Hosseni Nejad Mir N and Faraji F and Mozhdehipanah H and Modara F and Navardi S and Heidari H and Ayoubi S and Naser Moghadasi A and Eskandarieh S}, title = {Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years}, journal = {Multiple Sclerosis and Related Disorders}, volume = {61}, number = {}, pages = {-}, year = {2022} }
RIS	TY - JOUR AU - Ghadiri F AU - Sahraian MA AU - Baghbanian SM AU - Ashtari F AU - Razazian N AU - Majdinasab N AU - Poursadeghfard M AU - Hatamian H AU - Harirchian MH AU - Beladimoghadam N AU - Azimi A AU - Sharifipour E AU - Hosseini S AU - Bayat A AU - Kamali H AU - Hosseni Nejad Mir N AU - Faraji F AU - Mozhdehipanah H AU - Modara F AU - Navardi S AU - Heidari H AU - Ayoubi S AU - Naser Moghadasi A AU - Eskandarieh S TI - Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years JO - Multiple Sclerosis and Related Disorders VL - 61 IS - SP - EP - PY - 2022 ER -

Style

Citing Format

MLA

Ghadiri F, et al.. "Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years." Multiple Sclerosis and Related Disorders, vol. 61, no. , 2022, pp. -.

APA

Ghadiri F, Sahraian MA, Baghbanian SM, Ashtari F, Razazian N, Majdinasab N, Poursadeghfard M, Hatamian H, Harirchian MH, Beladimoghadam N, Azimi A, Sharifipour E, Hosseini S, Bayat A, Kamali H, Hosseni Nejad Mir N, Faraji F, Mozhdehipanah H, Modara F, ... Eskandarieh S (2022). Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years. Multiple Sclerosis and Related Disorders, 61(), -.

Chicago

Ghadiri F, Sahraian MA, Baghbanian SM, Ashtari F, Razazian N, Majdinasab N, Poursadeghfard M, et al.. "Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years." Multiple Sclerosis and Related Disorders 61, no. (2022): -.

Harvard

Ghadiri F et al. (2022) 'Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years', Multiple Sclerosis and Related Disorders, 61(), pp. -.

Vancouver

Ghadiri F, Sahraian MA, Baghbanian SM, Ashtari F, Razazian N, Majdinasab N, et al.. Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years. Multiple Sclerosis and Related Disorders. 2022;61():-.

BibTex

@article{ author = {Ghadiri F and Sahraian MA and Baghbanian SM and Ashtari F and Razazian N and Majdinasab N and Poursadeghfard M and Hatamian H and Harirchian MH and Beladimoghadam N and Azimi A and Sharifipour E and Hosseini S and Bayat A and Kamali H and Hosseni Nejad Mir N and Faraji F and Mozhdehipanah H and Modara F and Navardi S and Heidari H and Ayoubi S and Naser Moghadasi A and Eskandarieh S}, title = {Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years}, journal = {Multiple Sclerosis and Related Disorders}, volume = {61}, number = {}, pages = {-}, year = {2022} }

RIS

TY - JOUR
AU - Ghadiri F
AU - Sahraian MA
AU - Baghbanian SM
AU - Ashtari F
AU - Razazian N
AU - Majdinasab N
AU - Poursadeghfard M
AU - Hatamian H
AU - Harirchian MH
AU - Beladimoghadam N
AU - Azimi A
AU - Sharifipour E
AU - Hosseini S
AU - Bayat A
AU - Kamali H
AU - Hosseni Nejad Mir N
AU - Faraji F
AU - Mozhdehipanah H
AU - Modara F
AU - Navardi S
AU - Heidari H
AU - Ayoubi S
AU - Naser Moghadasi A
AU - Eskandarieh S
TI - Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years
JO - Multiple Sclerosis and Related Disorders
VL - 61
IS -
SP -
EP -
PY - 2022
ER -

Science Communicator Platform

Authors

Abstract